State of Alaska Department of Revenue Has $6.04 Million Holdings in United Therapeutics Corporation $UTHR

State of Alaska Department of Revenue trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 26.2% in the 3rd quarter, Holdings Channel reports. The fund owned 14,407 shares of the biotechnology company’s stock after selling 5,125 shares during the quarter. State of Alaska Department of Revenue’s holdings in United Therapeutics were worth $6,039,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of UTHR. AQR Capital Management LLC raised its stake in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Invesco Ltd. increased its holdings in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Assetmark Inc. raised its position in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. Norges Bank bought a new stake in shares of United Therapeutics in the second quarter valued at about $136,453,000. Finally, Amundi lifted its stake in shares of United Therapeutics by 3.6% in the second quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock valued at $107,113,000 after buying an additional 12,633 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $485.43, for a total transaction of $4,029,069.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $17,854,600.83. This represents a 18.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jan Malcolm sold 50 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total value of $25,606.00. Following the sale, the director directly owned 420 shares of the company’s stock, valued at $215,090.40. This represents a 10.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 608,514 shares of company stock valued at $284,376,421. Insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on UTHR. Jefferies Financial Group restated a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Wells Fargo & Company boosted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright increased their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Price Performance

United Therapeutics stock opened at $483.23 on Friday. The firm has a market capitalization of $20.81 billion, a P/E ratio of 18.31, a P/E/G ratio of 2.51 and a beta of 0.84. The stock has a fifty day moving average price of $483.94 and a two-hundred day moving average price of $402.27. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.39 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.